Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.74 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.74 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.74 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592933 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL10123477 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL9760793 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL9760600 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL593794 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL24712916 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL9759995 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL19116123 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL10109673 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A | |
| SCHEMBL5522889 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4NR3C1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698375-B1 | TGR5 modulators and method of use thereof | INTERCEPT PHARMACEUTICALS INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20180016295-A1 | TGR5 Modulators and Methods of Use Thereof | INTERCEPT PHARMACEUTICALS INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180016295-A1 | TGR5 Modulators and Methods of Use Thereof | INTERCEPT PHARMACEUTICALS INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-9650409-B2 | TGR5 modulators and methods of use thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650409-B2 | TGR5 modulators and methods of use thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-8445472-B2 | TGR5 modulators and methods of use thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445472-B2 | TGR5 modulators and methods of use thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120115832-A1 | TGR5 Modulators and Methods of Use Thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115832-A1 | TGR5 Modulators and Methods of Use Thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8114862-B2 | TGR5 modulators and methods of use thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114862-B2 | TGR5 modulators and methods of use thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100152151-A1 | TGR5 MODULATORS AND METHODS OF USE THEROF | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152151-A1 | TGR5 MODULATORS AND METHODS OF USE THEROF | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010059853-A1 | TGR5 MODULATORS AND METHOD OF USE THEREOF | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115832-A1 | TGR5 Modulators and Methods of Use Thereof | GPBAR1, SLC10A1, SLC5A1 | GPBAR1 1/4885NR1H4 23/4885NR3C1 670/4885 |
| US-20100152151-A1 | TGR5 MODULATORS AND METHODS OF USE THEROF | SLC10A1, GPBAR1, SLC5A1 | GPBAR1 2/4885NR1H4 18/4885NR3C1 774/4885 |
| US-20180016295-A1 | TGR5 Modulators and Methods of Use Thereof | GPBAR1, SLC10A1, SLC5A1 | GPBAR1 1/4885NR1H4 23/4885NR3C1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.